Vaccine Effectiveness against Symptomatic SARS-CoV-2 Infection in Adults Aged 65 Years and Older in Primary Care: I-MOVE-COVID-19 Project, Europe, December 2020 to May 2021
Esther Kissling
(1)
,
Mariëtte Hooiveld
(2)
,
Virginia Sandonis Martin
(3)
,
Iván Martinez-Baz
(4, 5)
,
Naoma William
(6)
,
Ana-Maria Vilcu
(7)
,
Clara Mazagatos
(5, 3)
,
Lisa Domegan
(8)
,
Simon De Lusignan
(9)
,
Adam Meijer
(10)
,
Ausenda Machado
(11)
,
Mia Brytting
(12)
,
Itziar Casado
(4, 5)
,
Josephine-L K. Murray
(6)
,
Sylvie Belhillil
(13, 14)
,
Amparo Larrauri
(5, 3)
,
Joan O'Donnell
(8)
,
Ruby Tsang
(9)
,
Marit De Lange
(10)
,
Ana Paula Rodrigues
(11)
,
Maximilian Riess
(12)
,
Jesus Castilla
(4, 5)
,
Mark Hamilton
(6)
,
Alessandra Falchi
(15, 16)
,
Francisco Pozo
(3)
,
Linda Dunford
(17)
,
Jade Cogdale
(18)
,
Tessa Jansen
(2)
,
Raquel Guiomar
(11)
,
Theresa Enkirch
(12)
,
Cristina Burgui
(4, 5)
,
Debbie Sigerson
(6)
,
Thierry Blanchon
(7)
,
Eva Maria Martinez Ochoa
(19)
,
Jeff Connell
(17)
,
Joanna Ellis
(18)
,
Rianne Van Gageldonk-Lafeber
(10)
,
Irina Kislaya
(11)
,
Angela Mc Rose
(1)
,
Marta Valenciano
(1)
1
EpiConcept [Paris]
2 NIVEL - Netherlands Institute for Health Services Research [Utrecht]
3 ISC - Instituto de Salud Carlos III [Madrid]
4 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
5 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
6 Public Health Scotland
7 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
8 HSE - Health Service Executive [Dublin]
9 University of Oxford
10 RIVM - National Institute for Public Health and the Environment [Bilthoven]
11 INSA - Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal]
12 Public Health Agency of Sweden
13 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
14 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
15 Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli]
16 INSERM - Institut National de la Santé et de la Recherche Médicale
17 UCD - University College Dublin [Dublin]
18 Public Health England [London]
19 Dirección General de Salud Pública
2 NIVEL - Netherlands Institute for Health Services Research [Utrecht]
3 ISC - Instituto de Salud Carlos III [Madrid]
4 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
5 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
6 Public Health Scotland
7 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
8 HSE - Health Service Executive [Dublin]
9 University of Oxford
10 RIVM - National Institute for Public Health and the Environment [Bilthoven]
11 INSA - Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal]
12 Public Health Agency of Sweden
13 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
14 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
15 Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli]
16 INSERM - Institut National de la Santé et de la Recherche Médicale
17 UCD - University College Dublin [Dublin]
18 Public Health England [London]
19 Dirección General de Salud Pública
Esther Kissling
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1089378
Connectez-vous pour contacter l'auteur
Adam Meijer
- Fonction : Auteur
- PersonId : 1378611
- ORCID : 0000-0001-8074-7582
Résumé
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥q 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45\textendash 74) for one dose only and 89% (95% CI: 79\textendash 94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
Domaines
Sciences du Vivant [q-bio]| Origine | Publication financée par une institution |
|---|---|
| Licence |
